Register Login

Aquestive Therapeutics Inc (AQST)

  • Event
  • July 11, 2022, 14:14 UTC

(10% Negative) Aquestive Therapeutics, Inc. (AQST) Announces Delay in study Trials for its AQST-109 epinephrine oral film Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 12:40 p.m.

    📋 Aquestive Therapeutics, Inc. (AQST) - Clinical Trial Update

    Filing Date: 2022-07-11

    Accepted: 2022-07-11 10:14:07

    Event Type: Clinical Trial Update

    Event Details:

    Aquestive Therapeutics Inc (AQST) Announces Clinical Trial Update Aquestive Therapeutics Inc (AQST) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: study
    • Diseases/Conditions: its AQST-109 epinephrine oral film
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: EPIPHAST

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aquestive Therapeutics Inc
    • CIK: 0001398733
    • Ticker Symbol: AQST
    • Period End Date: 2022-07-11
    • Document Type: 8-K

Search

News categories